Rich, clinic-ready pipeline with multiple parallel programs
Our discovery platform has led to impactful therapies that change disease progression across several clinical modalities:
Synedgen’s platform validation includes MIIST113 (SNSP113), now out-licensed to Synspira Inc. (Framingham, MA), and the lead asset is currently in Phase 2 clinical trials.
Synedgen’s therapies are designed to provide relief from gastrointestinal side effects of cancer radiation therapy and improve mucosal healing in inflammatory bowel diseases.
Synedgen has completed pilot clinical trials for its sinus health product. This portfolio is being developed for acute and chronic rhinosinusitis.
Synedgen has been awarded a 3 year grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to develop molecules intended to counteract severe, ulcerative eye injury.